조사회사 : MarketsandMarkets (마켓츠앤마켓츠) 출판년월 : 2024년07월
DNA Diagnostics Market – Global Forecast to 2029
DNA 진단 시장 : 제품(기기, 시약 및 키트, 서비스 및 소프트웨어), 기술(PCR, 질량 분석, 마이크로어레이), 용도[감염(간염, HIV, HPV), 종양학], 시료(혈액, 소변), 시장 규모, 점유율 , 추세 – 2029년까지의 세계 예측
DNA Diagnostics Market Size, Share & Trends by Product (Instruments, Reagents & Kits, Services & Software), Technology (PCR, Mass Spectroscopy, Microarrays), Application (Infectious Disease (Hepatitis, HIV, HPV), Oncology), Specimen (Blood, Urine) – Global Forecast to 2029
| 페이지 수 | 334 |
| 도표 수 | 398 |
| 가격 | |
| Single User License | USD 4,950 |
| Multi User License | USD 6,650 |
| Corporate License | USD 8,150 |
| Enterprise License | USD 10.000 |
| 구성 | 영문조사보고서 |
Report Overview
The global DNA diagnostics market is valued at an estimated USD 13.3 billion in 2024 and is projected to reach USD 21.2 billion by 2029, at a CAGR of 9.7% during the forecast period.
전 세계 DNA 진단 시장은 2024년에 133억 달러로 추정되며, 예측 기간 동안 CAGR은 9.7%로 2029년까지 212억 달러에 이를 것으로 예측됩니다.
Growth in the DNA diagnostics market is primarily driven by the increasing prevalence of chronic and infectious diseases, advancements in DNA diagnostics for personalized medicine, and increasing funding by healthcare-based companies. Personalized medicines help in making informed clinical decisions and alleviating the risk of adverse events. Thus, the increasing demand for personalized medicines is expected to offer significant growth opportunities for players operating in the DNA diagnostics market in the coming years.
“The reagents & kits segment is projected to witness highest growth rate in the DNA diagnostics market, by offering, during the forecast period”
Based on offering, the DNA diagnostics market is segmented into reagents & kits, instruments, and services & software. The frequent need for reagents & kits makes them a recurrent cost, and this recurrent purchasing requirement is one of the key contributors to market growth. The versatility of reagents & kits in accommodating diverse testing needs contributes to their extensive usage and market demand during the forecast period.
“The polymerase chain reaction (PCR) segment is projected to witness the highest growth rate in the DNA diagnostics market, by technology, during the forecast period.”
Based on technology, the DNA diagnostics market is segmented into polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies. PCR techniques have undergone extensive standardization, ensuring consistent and reliable results across different laboratories and platforms. Currently, PCR is one of the most widely used technologies in diagnostics due to its ease of use, cost-effectiveness, and quick turnaround time (4 to 6 hours). Small PCR instruments may need little or no maintenance. These factors are contributing to growth of this segment.
“The blood, serum, and plasma segment accounted for the largest market share of DNA diagnostics market, in 2023, by specimen”
Based on specimen, the DNA diagnostics market is segmented into blood, serum, and plasma, urine, and other specimens. Blood collection and processing procedures have undergone extensive standardization, ensuring consistent sample quality and reliability of test results. Standardized protocols and quality control measures enhance the accuracy and reproducibility of DNA diagnostic tests performed on blood samples. Which accounts for the largest market share of this segment in the DNA diagnostics market in 2023.
“The oncology testing segment is projected to witness the highest growth rate in the DNA diagnostics market, by application, during the forecast period”.
Based on application, the DNA diagnostics market is segmented into infectious disease diagnostics, oncology testing, prenatal, pre-implantation, myogenic disorders, and other applications. The surge in demand for oncology testing is fueled by various factors that are transforming the landscape of cancer diagnostics and treatment. DNA diagnostic tests enable physicians to study the predisposition of genetic materials to diseases and diagnose diseases, such as cancer, at an early stage. The growth of this segment is also driven by technological advancements and the increasing incidence of cancer.
“The diagnostic laboratories segment accounted for the largest share of the DNA diagnostics market in 2023, by end user”.
Based on end users, the DNA diagnostics market is segmented into hospitals and clinics, diagnostic laboratories, and other end users. Hospitals have increasingly outsourced diagnostic tests to diagnostic laboratories to reduce the costs and technical issues in managing laboratories. Many small and medium-sized private hospitals and clinics have adopted this trend, thereby driving growth in this segment.
“The Asia Pacific region is projected to witness highest growth rate in the DNA diagnostics market during the forecast period”
The global DNA diagnostics market is segmented into six regions – North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. The Asia Pacific is projected to register the highest CAGR in the DNA diagnostics market during the forecast period. Due to factors like government initiatives to raise awareness about early disease detection and routine health checkups, steadily rising healthcare costs, an increase in hospitals and clinical diagnostics laboratories in China and India, and strengthening research bases for diagnostic procedures across China, Japan, and India, the Asia Pacific market is anticipated to grow at the highest rate during the forecast period.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
- By Designation: C-level – 27%, D-level – 18%, and Others – 55%
- By Region: North America – 35%, Europe – 26%, Asia Pacific – 24%, Latin America – 12%, Middle East & Africa – 2%, and the GCC Countries – 1%
Lists of Companies Profiled in the Report:
Illumina, Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux (France), Hologic, Inc. (US), QIAGEN (Germany), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Revvity, Inc. (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A. (Italy), Grifols S.A. (Spain), Quidelortho Corporation (US), Amoy Diagnostics Co., Ltd (China), Molbio Diagnostics Pvt. Ltd. (India), Biocartis (Belgium), Exact Sciences Corporation (US), TBG Diagnostics Ltd (Australia), Genetic Signatures (Australia), and Vela Diagnostics (Singapore).
Research Coverage:
In this report, the DNA diagnostics market has been categorized based on technology (polymerase chain reaction (PCR), microarrays, in situ hybridization, sequencing technology, mass spectroscopy, and other technologies), specimen (blood, serum, and plasma, urine, and other specimens), offering (reagents & kits, instruments, and services & software), end user (diagnostic laboratories, hospitals & clinics, application (infectious disease diagnostic, oncology testing, prenatal, pre-implantation, myogenic disorder, and other applications), and region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries).
The report’s coverage includes comprehensive details about the key factors impacting the growth of the DNA diagnostics market, including opportunities, challenges, opportunities, and restraints. To offer insights into their business overview, services offered, significant strategies, acquisitions, and partnerships, product launches, and other recent developments related to the DNA diagnostics market, a thorough analysis of the major industry players has been conducted. This study examines the competitive landscape of emerging DNA diagnostics startups.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall DNA diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, trends, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers: (Rising incidence of chronic and infectious diseases, Rising focus on R&D and increased funding by healthcare-based companies, Growing demand for early disease diagnosis an dpersonalized medicine in developing countries, and Technological advancements in DNA diagnostics industry), challenges (Changing regulatory landscape for IVD and DNA diagnostics in US and European Union, Operational barriers and shortage of skills across major markets, and Introductio of alternatives technologies for disease detection and diagnosis), opportunities (Growing significance of companion diagnostics in drug development process, Increasing growth opportunities for DNA diagnostic companies in emerging economies, Advancements in bioinformatics and artificial intelligence in DNA diagnostics and Expansion of direct-to-consumer (DTC) genetic tetsing), and restraints (Unfavourable reimbursement scenario for diagnostic companies, High cost of DNA diagnostic instruments, and Ethical and privacy concerns associated with DNA diagnosis) influencing the growth of the in DNA diagnostics market.
• Product Development/Innovation: Detailed insights on research & development activities and new product launches and approvals in the DNA diagnostics market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the DNA diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the DNA diagnostics market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Illumina, Inc. (US), Danaher Corporation (US), and F. Hoffmann-La Roche Ltd. (Switzerland) are among others, in the DNA diagnostics market strategies.
Table of Contents
1 INTRODUCTION 43
1.1 STUDY OBJECTIVES 43
1.2 MARKET DEFINITION 43
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY 44
1.3 STUDY SCOPE 44
1.3.1 MARKET SEGMENTATION 44
1.3.2 REGIONAL SEGMENTATION 45
1.3.3 YEARS CONSIDERED 45
1.4 CURRENCY CONSIDERED 46
1.5 STAKEHOLDERS 46
1.6 RECESSION IMPACT 46
2 RESEARCH METHODOLOGY 47
2.1 RESEARCH DATA 47
FIGURE 1 DNA DIAGNOSTICS MARKET: RESEARCH DESIGN 47
2.1.1 SECONDARY DATA 48
2.1.1.1 Key data from secondary sources 49
2.1.2 PRIMARY DATA 49
2.1.2.1 Primary sources 49
2.1.2.2 Key data from primary sources 50
2.1.2.3 Key industry insights 51
2.1.2.4 Breakdown of primary interviews 51
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 51
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 52
2.2 MARKET SIZE ESTIMATION 52
2.2.1 BOTTOM-UP APPROACH 52
2.2.1.1 Approach 1: Company revenue estimation approach 53
FIGURE 4 DNA DIAGNOSTICS MARKET: REVENUE SHARE ANALYSIS 53
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 54
2.2.2 TOP-DOWN APPROACH 55
FIGURE 6 DNA DIAGNOSTICS MARKET: TOP-DOWN APPROACH 55
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 56
FIGURE 7 DATA TRIANGULATION METHODOLOGY 56
2.4 MARKET SHARE ANALYSIS 57
2.5 STUDY ASSUMPTIONS 57
2.6 GROWTH RATE ASSUMPTIONS 57
2.7 RESEARCH LIMITATIONS 58
2.7.1 METHODOLOGY-RELATED LIMITATIONS 58
2.7.2 SCOPE-RELATED LIMITATIONS 58
2.8 RISK ASSESSMENT 58
TABLE 1 RISK ASSESSMENT 58
2.9 RECESSION IMPACT ON DNA DIAGNOSTICS MARKET 59
3 EXECUTIVE SUMMARY 60
FIGURE 8 DNA DIAGNOSTICS MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION) 60
FIGURE 9 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 61
FIGURE 10 DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION) 61
FIGURE 11 DNA DIAGNOSTICS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 62
FIGURE 12 DNA DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 63
FIGURE 13 GEOGRAPHIC SNAPSHOT OF DNA DIAGNOSTICS MARKET 64
4 PREMIUM INSIGHTS 65
4.1 DNA DIAGNOSTICS MARKET OVERVIEW 65
FIGURE 14 RISING PREVALENCE OF CHRONIC, GENETIC, AND INFECTIOUS DISEASES TO DRIVE MARKET 65
4.2 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY AND COUNTRY (2023) 66
FIGURE 15 PCR SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023 66
4.3 DNA DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 67
FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH RATE IN DNA DIAGNOSTICS MARKET FROM 2024 TO 2029 67
4.4 DNA DIAGNOSTICS MARKET: REGIONAL MIX (2024–2029) 67
FIGURE 17 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 67
4.5 DNA DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS 68
FIGURE 18 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 68
5 MARKET OVERVIEW 69
5.1 INTRODUCTION 69
5.2 MARKET DYNAMICS 69
FIGURE 19 DNA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 69
5.2.1 DRIVERS 70
5.2.1.1 Rising incidence of chronic, infectious, and genetic diseases 70
FIGURE 20 INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2045 (MILLION) 72
5.2.1.2 Rising focus on R&D and increased funding by healthcare companies 72
5.2.1.3 Growing demand for early disease diagnosis and personalized medicine in developing countries 73
5.2.1.4 Technological advancements in DNA diagnostics industry 74
5.2.2 RESTRAINTS 75
5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies 75
5.2.2.2 High cost of DNA diagnostic instruments 76
5.2.2.3 Ethical and privacy concerns associated with DNA diagnosis 76
5.2.3 OPPORTUNITIES 76
5.2.3.1 Growing significance of companion diagnostics in drug development process 76
5.2.3.2 Increasing growth opportunities for DNA diagnostic companies in emerging economies 77
5.2.3.3 Advancements in bioinformatics and artificial intelligence in DNA diagnostics 77
5.2.3.4 Expansion of direct-to-consumer (DTC) genetic testing 78
5.2.4 CHALLENGES 78
5.2.4.1 Changing regulatory landscape for IVD and DNA diagnostics in US and European Union 78
5.2.4.2 Operational barriers and shortage of skills across major markets 79
5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis 79
5.3 PRICING ANALYSIS 80
5.3.1 PRICING ANALYSIS, BY REGION 80
TABLE 2 AVERAGE SELLING PRICE OF DNA DIAGNOSTIC PRODUCTS, BY REGION, 2021–2023 80
5.3.2 PRICING ANALYSIS, BY PRODUCT 81
TABLE 3 PRICING ANALYSIS OF DNA DIAGNOSTIC PRODUCTS, 2021–2023 81
5.4 VALUE CHAIN ANALYSIS 81
FIGURE 21 VALUE CHAIN ANALYSIS OF DNA DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE 82
5.5 SUPPLY CHAIN ANALYSIS 83
FIGURE 22 DNA DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 83
5.6 ECOSYSTEM ANALYSIS 84
FIGURE 23 DNA DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 84
5.6.1 DNA DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 84
5.7 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 4 DNA DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 85
FIGURE 24 DNA DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 86
5.7.1 THREAT OF NEW ENTRANTS 86
5.7.2 THREAT OF SUBSTITUTES 86
5.7.3 BARGAINING POWER OF BUYERS 87
5.7.4 BARGAINING POWER OF SUPPLIERS 87
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 87
5.8 REGULATORY ANALYSIS 87
5.8.1 NORTH AMERICA 87
5.8.1.1 US 87
5.8.1.2 Canada 88
5.8.2 EUROPE 88
TABLE 5 EUROPE: CLASSIFICATION OF DEVICES 88
5.8.3 ASIA PACIFIC 89
5.8.3.1 China 89
5.8.3.2 Japan 89
TABLE 6 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89
5.8.3.3 India 89
5.8.4 LATIN AMERICA 90
5.8.4.1 Brazil 90
5.8.4.2 Mexico 90
5.8.5 MIDDLE EAST 90
5.8.6 AFRICA 91
5.8.7 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
5.9 TECHNOLOGY ANALYSIS 93
5.9.1 KEY TECHNOLOGIES 93
5.9.1.1 Polymerase chain reaction 93
5.9.2 COMPLEMENTARY TECHNOLOGIES 93
5.9.2.1 Sequencing technology 93
5.9.2.2 DNA microarrays 94
5.9.3 ADJACENT TECHNOLOGIES 94
5.9.3.1 Isothermal nucleic acid amplification technology 94
5.10 TRADE ANALYSIS 94
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 94
TABLE 12 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2023 (USD MILLION) 94
TABLE 13 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2023 (USD MILLION) 95
5.11 PATENT ANALYSIS 95
FIGURE 25 PATENT ANALYSIS FOR DNA DIAGNOSTICS (JANUARY 2013–DECEMBER 2023) 95
5.11.1 LIST OF MAJOR PATENTS 96
5.12 KEY CONFERENCES AND EVENTS IN 2024–2025 97
TABLE 14 DNA DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2024–2025 97
5.13 PESTLE ANALYSIS 99
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 100
5.14.1 REVENUE SHIFT IN DNA DIAGNOSTICS MARKET 100
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 101
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 101
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DNA DIAGNOSTIC END USERS 101
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DNA DIAGNOSTIC END USERS (%) 101
5.15.2 BUYING CRITERIA 101
FIGURE 27 KEY BUYING CRITERIA FOR DNA DIAGNOSTIC END USERS 101
TABLE 16 KEY BUYING CRITERIA FOR DNA DIAGNOSTIC END USERS 102
5.16 INVESTMENT & FUNDING SCENARIO 102
FIGURE 28 DNA DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO 102
6 DNA DIAGNOSTICS MARKET, BY OFFERING 103
6.1 INTRODUCTION 104
TABLE 17 DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 104
TABLE 18 PRICE OF DNA DIAGNOSTIC PRODUCTS (2023) 104
6.2 REAGENTS & KITS 105
6.2.1 RECURRENT PURCHASE FOR DIAGNOSTICS TO PROPEL MARKET 105
TABLE 19 DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY REGION, 2022–2029 (USD MILLION) 106
TABLE 20 NORTH AMERICA: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 21 EUROPE: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 22 ASIA PACIFIC: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 23 LATIN AMERICA: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 108
6.3 INSTRUMENTS 108
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET 108
TABLE 24 KEY INSTRUMENTS AVAILABLE IN MARKET 109
TABLE 25 DNA DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 109
TABLE 26 NORTH AMERICA: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 27 EUROPE: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 28 ASIA PACIFIC: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 29 LATIN AMERICA: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 111
6.4 SERVICES & SOFTWARE 111
6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH 111
TABLE 30 DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION) 112
TABLE 31 NORTH AMERICA: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 32 EUROPE: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 33 ASIA PACIFIC: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 34 LATIN AMERICA: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 114
7 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY 115
7.1 INTRODUCTION 116
TABLE 35 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 116
7.2 POLYMERASE CHAIN REACTION 116
7.2.1 GROWING USE OF PCR IN GENOMICS TO DRIVE MARKET 116
TABLE 36 DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION) 117
TABLE 37 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 38 EUROPE: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 39 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 40 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION) 119
7.3 MICROARRAY 119
7.3.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS 119
TABLE 41 DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY REGION, 2022–2029 (USD MILLION) 120
TABLE 42 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 43 EUROPE: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 44 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 45 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR MICROARRAY, BY COUNTRY, 2022–2029 (USD MILLION) 122
7.4 IN SITU HYBRIDIZATION 122
7.4.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET 122
TABLE 46 DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022–2029 (USD MILLION) 123
TABLE 47 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 48 EUROPE: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 49 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 50 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 125
7.5 SEQUENCING 125
7.5.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET 125
TABLE 51 DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY REGION, 2022–2029 (USD MILLION) 126
TABLE 52 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 53 EUROPE: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 54 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 55 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION) 128
7.6 MASS SPECTROSCOPY 128
7.6.1 TECHNOLOGICAL ADVANCEMENTS IN MASS SPECTROMETERS TO DRIVE ADOPTION 128
TABLE 56 DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION) 129
TABLE 57 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 58 EUROPE: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 59 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 60 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION) 131
7.7 OTHER TECHNOLOGIES 131
TABLE 61 DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION) 132
TABLE 62 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 63 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 64 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 65 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 134
8 DNA DIAGNOSTICS MARKET, BY SPECIMEN 135
8.1 INTRODUCTION 136
TABLE 66 DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 136
8.2 BLOOD, SERUM, AND PLASMA 136
8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET 136
TABLE 67 DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY REGION, 2022–2029 (USD MILLION) 137
TABLE 68 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 69 EUROPE: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 70 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 71 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 139
8.3 URINE 139
8.3.1 NONINVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH 139
TABLE 72 DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY REGION, 2022–2029 (USD MILLION) 140
TABLE 73 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 74 EUROPE: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 75 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 76 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 141
8.4 OTHER SPECIMENS 141
TABLE 77 DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY REGION, 2022–2029 (USD MILLION) 142
TABLE 78 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 142
TABLE 79 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 80 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 81 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 144
9 DNA DIAGNOSTICS MARKET, BY APPLICATION 145
9.1 INTRODUCTION 146
TABLE 82 DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 146
9.2 INFECTIOUS DISEASE DIAGNOSTICS 147
TABLE 83 DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 147
TABLE 84 DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2022–2029 (USD MILLION) 148
TABLE 85 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 86 EUROPE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 87 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 88 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION) 150
9.2.1 HEPATITIS 150
9.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive growth 150
TABLE 89 DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2022–2029 (USD MILLION) 151
TABLE 90 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 91 EUROPE: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 92 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 93 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION) 153
9.2.2 HIV 153
9.2.2.1 Increasing prevalence of HIV to propel market 153
TABLE 94 DNA DIAGNOSTICS MARKET FOR HIV, BY REGION, 2022–2029 (USD MILLION) 154
TABLE 95 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 96 EUROPE: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 97 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 98 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION) 155
9.2.3 CT/NG 155
9.2.3.1 Increasing prevalence of CT/NG infections to support market growth 155
TABLE 99 DNA DIAGNOSTICS MARKET FOR CT/NG, BY REGION, 2022–2029 (USD MILLION) 156
TABLE 100 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 101 EUROPE: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 102 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 103 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022–2029 (USD MILLION) 158
9.2.4 HPV 158
9.2.4.1 Technological advancements for preventing HPV infections to drive market 158
TABLE 104 DNA DIAGNOSTICS MARKET FOR HPV, BY REGION, 2022–2029 (USD MILLION) 159
TABLE 105 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 106 EUROPE: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 107 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 108 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022–2029 (USD MILLION) 160
9.2.5 OTHER INFECTIOUS DISEASES 160
TABLE 109 DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION) 161
TABLE 110 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 111 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 112 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 113 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 162
9.3 ONCOLOGY TESTING 163
9.3.1 GROWING SIGNIFICANCE OF PRECISION MEDICINE AND PERSONALIZED APPROACHES IN CANCER CARE TO DRIVE MARKET 163
TABLE 114 DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2022–2029 (USD MILLION) 164
TABLE 115 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 116 EUROPE: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 117 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 118 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 166
9.4 MYOGENIC DISORDERS 166
9.4.1 DIAGNOSIS OF VARIOUS MYOGENIC DISORDERS THROUGH DNA TESTING TO PROPEL MARKET 166
TABLE 119 DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY REGION, 2022–2029 (USD MILLION) 167
TABLE 120 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 167
TABLE 121 EUROPE: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 122 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 123 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 169
9.5 PRENATAL 169
9.5.1 INCREASING DEMAND FOR EARLY DETECTION OF GENETIC DISORDERS TO BOOST MARKET GROWTH 169
TABLE 124 DNA DIAGNOSTICS MARKET FOR PRENATAL, BY REGION, 2022–2029 (USD MILLION) 170
TABLE 125 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 126 EUROPE: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022–2029 (USD MILLION) 170
TABLE 127 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 128 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR PRENATAL, BY COUNTRY, 2022–2029 (USD MILLION) 171
9.6 PREIMPLANTATION 172
9.6.1 GROWING NUMBER OF FERTILITY CLINICS AND IVF CENTERS TO PROPEL MARKET 172
TABLE 129 NUMBER OF PREIMPLANTATION TESTS PERFORMED, BY COUNTRY, 2022–2029 172
TABLE 130 DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY REGION, 2022–2029 (USD MILLION) 173
TABLE 131 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 132 EUROPE: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 133 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 134 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022–2029 (USD MILLION) 175
9.7 OTHER APPLICATIONS 175
TABLE 135 DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 175
TABLE 136 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 137 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 138 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 139 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 177
10 DNA DIAGNOSTICS MARKET, BY END USER 178
10.1 INTRODUCTION 179
TABLE 140 DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 179
10.2 DIAGNOSTIC LABORATORIES 179
10.2.1 INCREASED OUTSOURCING OF DIAGNOSTIC TESTS BY HOSPITALS TO DRIVE MARKET 179
TABLE 141 DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 180
TABLE 142 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 180
TABLE 143 EUROPE: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 144 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 145 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 182
10.3 HOSPITALS & CLINICS 182
10.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST GROWTH 182
TABLE 146 DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION) 183
TABLE 147 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 148 EUROPE: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 149 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 150 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 185
10.4 OTHER END USERS 185
TABLE 151 DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION) 185
TABLE 152 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 153 EUROPE: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 154 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 187
TABLE 155 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 187
11 DNA DIAGNOSTICS MARKET, BY REGION 188
11.1 INTRODUCTION 189
TABLE 156 DNA DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 189
11.2 NORTH AMERICA 189
FIGURE 29 NORTH AMERICA: DNA DIAGNOSTICS MARKET SNAPSHOT 190
TABLE 157 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 158 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 191
TABLE 159 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 191
TABLE 160 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 192
TABLE 161 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 192
TABLE 162 NORTH AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 163 NORTH AMERICA: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 193
11.2.1 NORTH AMERICA: RECESSION IMPACT 193
11.2.2 US 194
11.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market 194
TABLE 164 US: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 194
TABLE 165 US: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 195
TABLE 166 US: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 195
TABLE 167 US: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 196
TABLE 168 US: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 196
TABLE 169 US: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 170 US: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 197
11.2.3 CANADA 197
11.2.3.1 Rising prevalence of cancer and availability of healthcare funding to support market growth 197
TABLE 171 CANADA: CANCER DEATHS, BY TYPE, 2024 (%) 197
TABLE 172 CANADA: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 198
TABLE 173 CANADA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 198
TABLE 174 CANADA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 198
TABLE 175 CANADA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 199
TABLE 176 CANADA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 199
TABLE 177 CANADA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 178 CANADA: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 200
11.3 EUROPE 200
TABLE 179 EUROPE: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 201
TABLE 180 EUROPE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 201
TABLE 181 EUROPE: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 202
TABLE 182 EUROPE: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 202
TABLE 183 EUROPE: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 202
TABLE 184 EUROPE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 185 EUROPE: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 203
11.3.1 EUROPE: RECESSION IMPACT 203
11.3.2 GERMANY 204
11.3.2.1 Favorable government policies and rising per capita disposable income to propel market 204
TABLE 186 GERMANY: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 204
TABLE 187 GERMANY: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 205
TABLE 188 GERMANY: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 205
TABLE 189 GERMANY: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 205
TABLE 190 GERMANY: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 206
TABLE 191 GERMANY: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 192 GERMANY: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 206
11.3.3 UK 207
11.3.3.1 Growing number of accredited diagnostic laboratories to drive market 207
TABLE 193 UK: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 207
TABLE 194 UK: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 208
TABLE 195 UK: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 208
TABLE 196 UK: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 209
TABLE 197 UK: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 198 UK: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 209
11.3.4 FRANCE 210
11.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market 210
TABLE 199 FRANCE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 211
TABLE 200 FRANCE: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 211
TABLE 201 FRANCE: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 211
TABLE 202 FRANCE: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 212
TABLE 203 FRANCE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 204 FRANCE: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 213
11.3.5 ITALY 213
11.3.5.1 Adoption of advanced diagnostic technologies to support market growth 213
TABLE 205 ITALY: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 214
TABLE 206 ITALY: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 214
TABLE 207 ITALY: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 214
TABLE 208 ITALY: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 215
TABLE 209 ITALY: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 210 ITALY: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 215
11.3.6 SPAIN 216
11.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players 216
TABLE 211 SPAIN: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 216
TABLE 212 SPAIN: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 217
TABLE 213 SPAIN: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 217
TABLE 214 SPAIN: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 217
TABLE 215 SPAIN: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 216 SPAIN: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 218
11.3.7 REST OF EUROPE 218
TABLE 217 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 219
TABLE 218 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 219
TABLE 219 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 220
TABLE 220 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 220
TABLE 221 REST OF EUROPE: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 221
TABLE 222 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 221
11.4 ASIA PACIFIC 222
FIGURE 30 ASIA PACIFIC: DNA DIAGNOSTICS MARKET SNAPSHOT 223
TABLE 223 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 224
TABLE 224 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 224
TABLE 225 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 224
TABLE 226 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 225
TABLE 227 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 225
TABLE 228 ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 229 ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 226
11.4.1 ASIA PACIFIC: RECESSION IMPACT 226
11.4.2 JAPAN 226
11.4.2.1 Universal healthcare reimbursement policy to support market growth 226
TABLE 230 JAPAN: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 227
TABLE 231 JAPAN: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 227
TABLE 232 JAPAN: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 228
TABLE 233 JAPAN: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 228
TABLE 234 JAPAN: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 235 JAPAN: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 229
11.4.3 CHINA 229
11.4.3.1 Rapid economic growth and greater public access to modern healthcare to drive market 229
TABLE 236 CHINA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 230
TABLE 237 CHINA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 230
TABLE 238 CHINA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 230
TABLE 239 CHINA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 231
TABLE 240 CHINA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 231
TABLE 241 CHINA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 242 CHINA: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 232
11.4.4 INDIA 232
11.4.4.1 Increased private & public investments and large patient population to drive market 232
TABLE 243 INDIA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 233
TABLE 244 INDIA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 234
TABLE 245 INDIA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 234
TABLE 246 INDIA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 235
TABLE 247 INDIA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 248 INDIA: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 236
11.4.5 REST OF ASIA PACIFIC 236
TABLE 249 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 237
TABLE 250 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 237
TABLE 251 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 237
TABLE 252 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 238
TABLE 253 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 238
TABLE 254 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 239
11.5 LATIN AMERICA 239
TABLE 255 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 240
TABLE 256 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 240
TABLE 257 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 240
TABLE 258 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 241
TABLE 259 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 241
TABLE 260 LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 242
TABLE 261 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 242
11.5.1 LATIN AMERICA: RECESSION IMPACT 242
11.5.2 BRAZIL 243
11.5.2.1 Improving healthcare infrastructure and stringent regulations to drive market 243
TABLE 262 BRAZIL: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 243
TABLE 263 BRAZIL: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 244
TABLE 264 BRAZIL: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 244
TABLE 265 BRAZIL: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 245
TABLE 266 BRAZIL: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 267 BRAZIL: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 246
11.5.3 MEXICO 246
11.5.3.1 Improving accessibility and affordability of healthcare services to aid market growth 246
TABLE 268 MEXICO: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 247
TABLE 269 MEXICO: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 247
TABLE 270 MEXICO: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 247
TABLE 271 MEXICO: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 248
TABLE 272 MEXICO: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 273 MEXICO: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 249
11.5.4 REST OF LATIN AMERICA 249
TABLE 274 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 250
TABLE 275 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 250
TABLE 276 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 251
TABLE 277 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 251
TABLE 278 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 279 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 252
11.6 MIDDLE EAST & AFRICA 253
11.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET 253
TABLE 280 AFRICA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022 254
TABLE 281 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 254
TABLE 282 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 254
TABLE 283 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 255
TABLE 284 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 255
TABLE 285 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 256
TABLE 286 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 256
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 256
11.7 GCC COUNTRIES 257
11.7.1 INCREASED GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR TO DRIVE MARKET 257
TABLE 287 GCC COUNTRIES: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 257
TABLE 288 GCC COUNTRIES: DNA DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 258
TABLE 289 GCC COUNTRIES: DNA DIAGNOSTICS MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 258
TABLE 290 GCC COUNTRIES: DNA DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 259
TABLE 291 GCC COUNTRIES: DNA DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION) 259
TABLE 292 GCC COUNTRIES: DNA DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 260
11.7.2 GCC COUNTRIES: RECESSION IMPACT 260
12 COMPETITIVE LANDSCAPE 261
12.1 OVERVIEW 261
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 261
12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN DNA DIAGNOSTICS MARKET 261
TABLE 293 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DNA DIAGNOSTICS MARKET 261
12.3 REVENUE ANALYSIS 263
FIGURE 31 REVENUE ANALYSIS OF TOP PLAYERS IN DNA DIAGNOSTICS MARKET, 2021–2023 (USD MILLION) 263
12.4 MARKET SHARE ANALYSIS 264
FIGURE 32 DNA DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2023) 264
TABLE 294 DNA DIAGNOSTICS MARKET: DEGREE OF COMPETITION 265
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 266
12.5.1 STARS 266
12.5.2 EMERGING LEADERS 266
12.5.3 PERVASIVE PLAYERS 266
12.5.4 PARTICIPANTS 266
FIGURE 33 DNA DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 267
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 267
12.5.5.1 Company footprint 267
TABLE 295 DNA DIAGNOSTICS MARKET: COMPANY FOOTPRINT 267
12.5.5.2 Offering footprint 268
TABLE 296 DNA DIAGNOSTICS MARKET: OFFERING FOOTPRINT 268
12.5.5.3 Technology footprint 268
TABLE 297 DNA DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 268
12.5.5.4 End-user footprint 269
TABLE 298 DNA DIAGNOSTICS MARKET: END-USER FOOTPRINT 269
12.5.5.5 Region footprint 270
TABLE 299 DNA DIAGNOSTICS MARKET: REGION FOOTPRINT 270
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 270
12.6.1 PROGRESSIVE COMPANIES 270
12.6.2 STARTING BLOCKS 270
12.6.3 RESPONSIVE COMPANIES 271
12.6.4 DYNAMIC COMPANIES 271
FIGURE 34 DNA DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 271
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 272
TABLE 300 DNA DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 272
12.7 VALUATION & FINANCIAL METRICS 273
FIGURE 35 EV/EBITDA OF KEY VENDORS 273
FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 273
12.8 BRAND/PRODUCT COMPARISON 274
FIGURE 37 DNA DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 274
12.9 COMPETITIVE SCENARIO 275
12.9.1 PRODUCT LAUNCHES & APPROVALS 275
TABLE 301 DNA DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2024 275
12.9.2 DEALS 276
TABLE 302 DNA DIAGNOSTICS MARKET: DEALS, JANUARY 2021–MAY 2024 276
12.9.3 EXPANSIONS 277
TABLE 303 DNA DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–MAY 2024 277
12.9.4 OTHER DEVELOPMENTS 277
TABLE 304 DNA DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024 277
13 COMPANY PROFILES 278
(Business overview, Products/Solutions/Services offered, Recent Developments, MnM view, Key strengths, Strategic choices, Weaknesses and competitive threats) *
13.1 KEY PLAYERS 278
13.1.1 DANAHER 278
TABLE 305 DANAHER: COMPANY OVERVIEW 278
FIGURE 38 DANAHER: COMPANY SNAPSHOT (2023) 279
TABLE 306 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED 279
TABLE 307 DANAHER: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2024 280
TABLE 308 DANAHER: DEALS, JANUARY 2021–MAY 2024 280
13.1.2 ILLUMINA, INC. 282
TABLE 309 ILLUMINA, INC.: COMPANY OVERVIEW 282
FIGURE 39 ILLUMINA INC.: COMPANY SNAPSHOT (2023) 283
TABLE 310 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 283
TABLE 311 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024 284
TABLE 312 ILLUMINA, INC.: DEALS, JANUARY 2021–MAY 2024 285
TABLE 313 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021–MAY 2024 286
TABLE 314 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024 286
13.1.3 F. HOFFMANN-LA ROCHE LTD. 288
TABLE 315 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 288
FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023) 289
TABLE 316 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 289
TABLE 317 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2024 291
TABLE 318 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–MAY 2024 292
13.1.4 BIOMÉRIEUX 294
TABLE 319 BIOMÉRIEUX: COMPANY OVERVIEW 294
FIGURE 41 BIOMÉRIEUX: COMPANY SNAPSHOT (2023) 295
TABLE 320 BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED 295
TABLE 321 BIOMÉRIEUX: PRODUCT APPROVALS, JANUARY 2021–MAY 2024 297
13.1.5 HOLOGIC, INC. 299
TABLE 322 HOLOGIC, INC.: COMPANY OVERVIEW 299
FIGURE 42 HOLOGIC, INC.: COMPANY SNAPSHOT (2023) 300
TABLE 323 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 300
TABLE 324 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024 301
TABLE 325 HOLOGIC, INC.: DEALS, JANUARY 2021–MAY 2024 301
13.1.6 ABBOTT LABORATORIES 303
TABLE 326 ABBOTT LABORATORIES: COMPANY OVERVIEW 303
FIGURE 43 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023) 304
TABLE 327 ABBOTT LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED 304
TABLE 328 ABBOTT LABORATORIES: PRODUCT APPROVALS, JANUARY 2021–MAY 2024 306
TABLE 329 ABBOTT LABORATORIES: DEALS, JANUARY 2021–MAY 2024 307
13.1.7 THERMO FISHER SCIENTIFIC INC. 308
TABLE 330 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 308
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 309
TABLE 331 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 309
TABLE 332 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–MAY 2024 311
13.1.8 QIAGEN 312
TABLE 333 QIAGEN: COMPANY OVERVIEW 312
FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2023) 313
TABLE 334 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 313
TABLE 335 QIAGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2024 315
TABLE 336 QIAGEN: DEALS, JANUARY 2021–MAY 2024 316
13.1.9 REVVITY, INC. 317
TABLE 337 REVVITY, INC.: COMPANY OVERVIEW 317
FIGURE 46 REVVITY, INC.: COMPANY SNAPSHOT (2023) 318
TABLE 338 REVVITY, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 318
TABLE 339 REVVITY, INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024 319
TABLE 340 REVVITY, INC.: DEALS, JANUARY 2021–MAY 2024 319
13.1.10 MYRIAD GENETICS, INC. 320
TABLE 341 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 320
FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023) 321
TABLE 342 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 321
TABLE 343 MYRIAD GENETICS, INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024 322
TABLE 344 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021–MAY 2024 322
13.1.11 SIEMENS HEALTHINEERS AG 323
TABLE 345 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 323
FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023) 324
TABLE 346 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED 324
*Details on Business overview, Products/Solutions/Services offered, Recent Developments, MnM view, Key strengths, Strategic choices, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 326
13.2.1 BECTON, DICKINSON AND COMPANY 326
13.2.2 GRIFOLS, S.A. 327
13.2.3 QUIDELORTHO CORPORATION 328
13.2.4 AGILENT TECHNOLOGIES, INC. 329
13.2.5 DIASORIN S.P.A. 330
13.2.6 EXACT SCIENCES CORPORATION 331
13.2.7 GENETIC SIGNATURES 332
13.2.8 BIOCARTIS 333
13.2.9 TBG DIAGNOSTICS LIMITED 334
TABLE 347 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW 334
13.2.10 VELA DIAGNOSTICS 335
TABLE 348 VELA DIAGNOSTICS: COMPANY OVERVIEW 335
13.2.11 AMOY DIAGNOSTICS CO., LTD. 336
TABLE 349 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW 336
13.2.12 MOLBIO DIAGNOSTICS PVT. LTD. 337
TABLE 350 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW 337
14 APPENDIX 338
14.1 DISCUSSION GUIDE 338
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 343
14.3 CUSTOMIZATION OPTIONS 345
14.4 RELATED REPORTS 345
14.5 AUTHOR DETAILS 347
